| Illumina Inc. (ILMN)
VCA Stocks: BioTechnology -> B2B Biotech -> DNA Sequencing
|5 Day Chart -- 6 Month Chart -- 2 Year Chart -- 5 Year Chart|
Illumina, Inc. (Illumina) is a developer and manufacturer of life science tools and integrated systems for the analysis of genetic variation and function.
The Company provides a line of genetic analysis solutions, with products and services that serve a range of interconnected markets, including sequencing, genotyping, gene expression, and molecular diagnostics. The Company is organized in two business segments: Life Sciences and Diagnostics. Its Life Sciences business unit includes all products and services related to the research market, namely the product lines based on its sequencing, BeadArray, VeraCode, and real-time PCR technologies. Its Diagnostics business unit focuses on molecular diagnostics. Its customers include genomic research centers, academic institutions, government laboratories, and clinical research organizations, as well as pharmaceutical, biotechnology, agrigenomics, and consumer genomics companies. The Company sells its products to a number of customers outside the United States, including customers in other areas of North America, Europe, and the Asia-Pacific region. In January 2011, the Company acquired Epicentre Technologies Corporation, a provider of nucleic acid sample preparation reagents and specialty enzymes for sequencing and microarray applications. In September 2012, it acquired BlueGnome Ltd. In February 2013, it completed the acquisition of Verinata Health, Inc. Effective July 23, 2013, Illumina Inc acquired Advanced Liquid Logic Inc.
In its deoxyribonucleic acid (DNA) sequencing systems, the Company applies the SBS biochemistry on microscopic clusters of DNA. Each cluster starts as a single DNA molecule fragment, typically a hundred bases long, attached to the inside surface of a flow cell. The Company then uses amplification biochemistry to create copies of each starting molecule. Its BeadArray technology combines microscopic beads and a substrate in a manufacturing process to produce arrays that can perform many assays simultaneously, enabling large-scale analysis of genetic variation and biological function. Its BeadArray technology consists of microscopic silica beads, each bead covered with hundreds of thousands of copies of oligonucleotides (oligos). The VeraCode technology platform leverages the power of digital holographic codes to provide a detection method for multiplex assays. VeraCode enables multiplexing from 1-384-plex in a single well. The VeraCode technology consists of cylindrical glass beads (measuring 240 microns in length by 28 microns in diameter) inscribed with a digital holographic code to designate and track the specific analyte or genotype of interest throughout the multiplex reaction. Real-Time PCR (PCR) is used to amplify and simultaneously quantify a targeted DNA molecule, with applications in gene expression, viral quantification, array data validation, pathogen detection, and genotyping.
Sequencing/Array Combination Platforms
The HiScanSQ combines its SBS sequencing technology and iScan microarray analysis instrumentation into one system, with a modular design that can evolve with changing research needs. This flexible system allows researchers to use its sequencing and array technologies interactively to bring increased power to their experiments.
The iScan supports its Infinium, GoldenGate, DASL, gene expression, and methylation assays. Its BeadXpress Reader is designed for both small and high-throughput laboratories conducting molecular testing with multiplexed-based assays deployed on our VeraCode bead technology. It supports a range of applications, including DNA, ribonucleic acid (RNA), and protein-based assays.
Its InfiniumHD Whole-Genome BeadChips represent its technologically advanced multi-sample DNA analysis microarrays, enabling the interrogation of up to 2.5 million markers per sample, depending on the BeadChip. In addition to the Omni family, the HumanOmni2.5 and HumanOmni1S BeadChips, provide common and rare variants identified by the 1000 Genomes Project for performing genome-wide association studies (GWAS) projects. This product line also includes agriculturally relevant genome panels, such as the BovineHD and MaizeSNP50 BeadChips. The Company offers iSelect Custom Genotyping BeadChips. Its GoldenGate Universal-32 Sample BeadChip provides a flexible customized solution for mid-plex genotyping assays performed on the iScan System or HiScan, while the VeraCode GoldenGate genotyping arrays are well-suited for low-plex genotyping on the BeadXpress Reader.
Real-time PCR Platforms
The Eco Real-Time PCR System provides qPCR results. Its user interface provides experimental design and setup, enabling the system to perform qPCR on 48 samples in less than 40 minutes.
The Company offers genotyping services to academic institutions, biotechnology, and pharmaceutical customers. The in-house molecular geneticists help customers perform GWAS projects, linkage analysis, and fine mapping studies. The Company employs a range of its products, including standard and custom GoldenGate, standard Infinium and Infinium HD, and iSelect Infinium assays.
Service Partnership Programs
The Company has developed partnered programs, such as its Certified Service Providers (CSPro) and Illumina Genome Network (IGN) to create a world-wide network of Illumina technology-enabled service offerings. There are over 50 Illumina CSPro-certified organizations worldwide providing sequencing, genotyping, and gene expression services using its technologies and products. The genome sequencing service network comprises CSPro-certified academic and commercial organizations possessing 10 or more HiSeq 2000 or Genome Analyzer systems.
Individual Genome Sequencing
Illumina’s Individual Genome Sequencing Service provides personal genome sequencing for consumers. It is performed in its CLIA-certified, CAP-accredited laboratory using its next-generation sequencing technology. The service is built around physician-patient consultation, with a physician’s order required to initiate the process. The offering includes sequencing of an individual’s DNA to 30-times depth, providing information on SNP variation and other structural characteristics of the genome, such as insertions, deletions, and rearrangements. The Company is collaborating with a number of partners to provide secondary data analysis, such as calculation of disease risk, ancestry, and information on traits of interest. The service requires individuals to follow its physician-mediated process, which involves pre-service consultation, patient consent, and a seven-day period, during which the patient may withdraw consent. The final genome data is returned to the physician, who in turn delivers it to the consumer.
The Company competes with Affymetrix, Inc., Agilent Technologies, Inc., Beckman Coulter, Inc., Complete Genomics, Inc., Helicos BioSciences Corporation, General Electric Company, Life Technologies Corporation, Luminex Corporation, Pacific Biosciences of California, Inc., QIAGEN N.V., Roche Diagnostics Corp. and Sequenom, Inc.
More Information for Illumina Inc. (ILMN):
Company Website - http://www.illumina.com
All-in-One Message Board from TheLion - Message Boards
SEC Quarterly Filings - SEC 10-Q
SEC Annual Filings - SEC 10-K
Conference Calls from Thomson Financial - Thomson StreetEvents
Conference Call Transcripts from SeekingAlpha.com - SeekingAlpha.com Transcripts
Insider Trading and Chart from Nasdaq - Insider Purchases and Sales
Reuters Finance Info - Reuters Profile
Yahoo Finance Info - Yahoo Finance
MSN Money Info - MSN Money
Google Finance Info - Google Finance
CBS MarketWatch Info - CBS MarketWatch
Google News Search - Google News
Google Blog Search - Google Blog Search
Motley Fool - Motley Fool Caps
TheStreet.com' Stockpickr - Stockpickr Holdings
Bloomberg - Bloomberg News